Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

2 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(75.0%)
Phase 4
2(25.0%)
8Total
N/A(6)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07379788Completed

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Role: lead

NCT05459701Phase 4Completed

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Role: lead

NCT05813132Not ApplicableCompleted

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Role: lead

NCT05289349Not ApplicableCompleted

Propofol or Sevoflurane Anesthesia in Egyptian Patients

Role: lead

NCT06313047Completed

Pharmacogenetic of Doxorubicin in HCC.

Role: lead

NCT05291039Not ApplicableCompleted

Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Role: lead

NCT05459389Not ApplicableCompleted

Early Targeted Antibiotic Therapy in Patients With Sepsis

Role: lead

NCT05291338Completed

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Role: lead

NCT03907423Not ApplicableCompleted

Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin

Role: lead

NCT04528212Phase 4Completed

Fenofibrate Versus Curcumin in Type 2 Diabetic Patients

Role: lead

NCT03912727Not ApplicableCompleted

Alpha Lipoic Acid Against Cardiovascular Events in Patients With Haemodialysis

Role: lead

NCT04133896Completed

Circulating IL-6, Clusterin and Irisin in Obese Subjects

Role: lead

All 12 trials loaded